share_log

J.W. Cole Advisors Inc. Has $88,000 Stock Holdings in VBI Vaccines Inc. (NASDAQ:VBIV)

Defense World ·  Sep 23, 2022 06:01

J.W. Cole Advisors Inc. trimmed its position in VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) by 27.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,100 shares of the biopharmaceutical company's stock after selling 20,000 shares during the period. J.W. Cole Advisors Inc.'s holdings in VBI Vaccines were worth $88,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. E Fund Management Co. Ltd. raised its holdings in VBI Vaccines by 98.1% during the 1st quarter. E Fund Management Co. Ltd. now owns 53,148 shares of the biopharmaceutical company's stock worth $88,000 after buying an additional 26,320 shares during the period. GSA Capital Partners LLP acquired a new stake in VBI Vaccines during the 4th quarter worth approximately $257,000. Nisa Investment Advisors LLC raised its holdings in VBI Vaccines by 1,099.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 126,800 shares of the biopharmaceutical company's stock worth $210,000 after buying an additional 116,230 shares during the period. Grimes & Company Inc. raised its holdings in VBI Vaccines by 19.6% during the 1st quarter. Grimes & Company Inc. now owns 281,077 shares of the biopharmaceutical company's stock worth $467,000 after buying an additional 46,116 shares during the period. Finally, Wealthsource Partners LLC acquired a new stake in VBI Vaccines during the 1st quarter worth approximately $238,000. 39.96% of the stock is currently owned by institutional investors and hedge funds.

Get VBI Vaccines alerts:

VBI Vaccines Price Performance

NASDAQ VBIV opened at $0.73 on Friday. The company has a quick ratio of 2.19, a current ratio of 2.29 and a debt-to-equity ratio of 0.20. VBI Vaccines Inc. has a 12-month low of $0.64 and a 12-month high of $3.49. The company has a market capitalization of $189.22 million, a PE ratio of -1.88 and a beta of 1.86. The firm's 50 day moving average is $0.93 and its 200-day moving average is $1.09.

VBI Vaccines (NASDAQ:VBIV – Get Rating) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.11). VBI Vaccines had a negative net margin of 15,391.36% and a negative return on equity of 75.37%. The business had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.70 million. Equities research analysts anticipate that VBI Vaccines Inc. will post -0.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Raymond James dropped their target price on shares of VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating on the stock in a report on Tuesday, August 9th.

About VBI Vaccines

(Get Rating)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

See Also

  • Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
  • What Steelcase's Earnings Say About the Return to the Office?
  • The Institutions Hold On To Darden Restaurants International
  • These 3 Big Dividend Payers Also Boast Strong Price Growth
  • Is The Golden Age Of Homebuilding Already Over?
  • Natural Gas Prices Continue To Rally, These Stocks Should Benefit

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment